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Abstract
Objective To study the impact of the 79A>C polymorphism
in the cytidine deaminase (CDA) gene on the pharmacoki-
netics of gemcitabine and its metabolite 2′,2′-difluorode-
oxyuridine (dFdU) in non-small-cell lung cancer (NSCLC)
patients.
Patients and methods Patients (n=20) received gemcitabine
1,125 mg/m
2 as a 30 min i.v. infusion as part of treatment for
NSCLC. Plasma samples were collected during 0–6 h after
gemcitabine administration. Gemcitabine and dFdU were
quantified by high performance liquid chromatography with
ultraviolet detection. The CDA 79A>C genotype was
determined with PCR and DNA sequencing.
Results Gemcitabine was rapidly cleared from plasma and
undetectable after 3 h. The allele frequency of the 79A>C
polymorphism was 0.40. Diplotypes were distributed as
A/A n=8, A/C n=8 ,and C/C n=4. No significant differ-
ences were found between the different CDA genotypes
and gemcitabine or dFdU AUC, clearance, or half-life.
Conclusion The 79A>C polymorphism in the CDA gene
does not have a major consistent and signficant impact on
gemcitabine pharmacokinetics.
Keywords Gemcitabine.Cytidine deaminase.
Pharmacogenetics.Pharmacokinetics.Genetic
polymorphism
Abbreviations
AUC Area under the curve
BSA Body surface area
CDA Cytidine deaminase
CrCL Creatinine clearance
dCDP Deoxycytidine diphosphate
dCTP Deoxycytidine triphosphate
dFdC Gemcitabine
dFdCMP Gemcitabine monophosphate
dFdCDP Gemcitabine diphosphate
dFdCTP Gemcitabine triphosphate
dFdU 2′,2′-Difluorodeoxyuridine
GFR Glomerular filtration rate
HPLC High performance liquid chromatography
NSCLC Non-small-cell lung cancer
RNR Ribonucleotide reductase
THU Tetrahydrouridine
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During the last decade, several new chemotherapeutic
agents have been evaluated for their beneficial effect in
patients with non-small-cell lung cancer (NSCLC). So far,
gemcitabine plus cisplatin has emerged as one of the
standard regimens for the treatment of advanced NSCLC
[1]. Nowadays, this regimen is mainly used in patients with
squamous cell histology [2].
Gemcitabine (2′,2′-difluorodeoxycytidine; dFdC) is a fluo-
ropyrimidine antimetabolite that is transported into cells by
equilibrative nucleoside transporters [3]. Within the cell,
gemcitabine is phosphorylated into gemcitabine monophos-
phate (dFdCMP) by deoxycytidine kinase (dCK) and thereaf-
ter into di- and triphosphates [4]. Gemcitabine triphosphate
(dFdCTP) is incorporated in DNA, and subsequently only one
deoxynucleotide molecule more can be inserted, which leads
to the halt of DNA synthesis [5]. This process is amplified
through inhibition of the enzyme ribonucleotide reductase
(RNR) by gemcitabine diphosphate (dFdCDP). Inhibition of
RNR leads to intracellular depletion of dCDP and dCTP,
which favours the incorporation of dFdCTP into DNA [6, 7].
Only a small part of the gemcitabine dose is responsible for
the cytotoxic effects, since more than 90% of the dose is
inactivated by the enzyme cytidine deaminase (CDA) into
2′,2′-difluorodeoxyuridine (dFdU). CDA is ubiquitous in the
humanbody,catalyzingthehydrolyticdeaminationof(deoxy-)
cytidineto (deoxy-)uridine. The totalenzyme capacity of CDA
in all organs and tissues determines the biotransformation rate
ofgemcitabineintodFdUandtherebyindirectlythedurationof
exposure to gemcitabine. Interestingly, cloning of human CDA
has revealed a 79A>C nonsynonymous coding single nucle-
otide polymorphism (cSNP) in exon 1 of the CDA gene
corresponding with two protein variants with more than
twofold difference in vitro deamination rates [8, 9]. The A
genotype corresponds to the wild type Lys-carrying enzyme
and the C genotype to a Gln-carrying variant (Gln27 CDA).
The wild type CDA enzyme has been reported to exert a 1.3-
to 3.3-fold higher deamination rate of cytarabine than Gln27
CDA [8]. Thus, the pharmacokinetics of gemcitabine may
also be affected by this genetic polymorphism.
The aim of the current study was to evaluate the impact
of the common 79A>C cSNP in the CDA gene on the
pharmacokinetics of gemcitabine and its metabolite dFdU
in gemcitabine-treated NSCLC patients.
Patients and methods
Patient selection
This study was performed as a site study of a phase III trial
of gemcitabine plus epirubicin versus gemcitabine plus
cisplatin in advanced NSCLC patients [10]. Patients had to
meet the inclusion and exclusion criteria of the main study.
In short, patients were included if they had stage III/IV
NSCLC. No prior chemotherapy was allowed. Radiotherapy
shouldhavebeencompletedatleast 4weeks beforeinclusion,
and patients should have recovered from any toxic side effect.
All patients had to have a performance status≤2a c c o r d i n gt o
theEasternCooperativeOncologyGroup(ECOG)scaleanda
life expectancy of at least 12 weeks. An adequate bone
marrow reserve and normal renal (creatinine clearance≥
60 ml/min) and liver function were required. The glomerular
filtration rate (GFR) was calculated according to the formula
of Cockcroft and Gault [11]. Patients were excluded if they
had active infections, second primary malignancies, uncor-
rected hypercalcemia, or an LVEF≤45% measured by
multiple gated acquisition (MUGA) scan. A detailed
description of the inclusion and exclusion criteria is
published elsewhere [10]. The local medical ethics commit-
tee of the hospital approved the protocol. All patients gave
written informed consent before study entry including
genotyping procedures.
Treatment and sample collection
Gemcitabine (Gemzar®, Lilly, Nieuwegein, the Netherlands)
ina doseof1,125 mg/m
2 in 250 mL 0.9% NaCl solution was
administered intravenously as a 30 min infusion. Patients co-
treated with epirubicin received the epirubicin dose after
completion of the gemcitabine infusion. The cisplatin dose
was administered the day after the gemcitabine infusion.
Blood sampling Blood sampling was carried out on the first
day of the first chemotherapy cycle. For pharmacokinetic
sampling, a cannula was placed intravenously in the arm of
the patient contralateral to the side of drug administration.
Blood samples of 9 mL were collected in heparinized tubes
containing 0.25 mg tetrahydrouridine (THU) in 50 μL
water, just before chemotherapy and at t=25, 40, 50, 60,
75, 90, 105, 120, 150, 180, 270, and 360 min after the start
of the gemcitabine infusion. Blood samples were immedi-
ately placed on ice and centrifuged at 2,500g for 10 min
within 1 h after collection. Plasma samples were stored at
−80°C until further analysis.
Genotyping material Harvesting of oral mucosa cells was
performed before chemotherapy by thorough mouth rinsing
for 30 s with 5 mL 0.9 % NaCl solution. The cell
suspension was collected in plastic cups and subsequently
placed on ice. Within 1 h after collection, the cell
suspension was centrifuged for 10 min at 190g at 4°C.
The supernatant was discarded and cells were washed in
10 mL ice cold phosphate buffered saline, pH=7.40 (PBS)
and centrifuged for 10 min at 190g at 4°C. The pellet was
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suspension was transferred to a microcentrifuge cup and
centrifuged briefly (15 s) at 10,000g. The supernatant was
discarded, and the pellet was kept frozen at −80°C until
further analysis.
Pharmacokinetic analysis
Gemcitabine hydrochloride and dFdU were obtained from
Eli Lilly (Indianapolis, IN). Tetrahydrouridine was purchased
from Calbiochem (La Jolla, CA). All other chemicals were
of standard analytical grade. The analysis of gemcitabine and
dFdU in plasma was carried out by high performance liquid
chromatography as described by Freeman et al. [12].
Cytidine deaminase genotyping
The CDA exon 1 polymorphism (C/A) at codon position 27
was genotyped by direct sequencing, in both directions, of
PCR-amplified genomic DNA.
First, the CDA region flanking the polymorphic site was
amplified using PCR with forward primer 5′- AGTAG
CTTCCCCTTCCAGTAGC and reverse primer 5′-CCTC
TTCCTGTACATCTTCCTCTG. The 25 μL reactions
contained 2.5 units Taq polymerase (Amersham Biosciences,
Uppsala, Sweden); 0.5 mM dNTP mix (Roche Diagnostics,
Mannheim, Germany); 1x PCR buffer (Roche Diagnostics),
0.05 mM MgCl2;0 . 2μM of each primer; and approximately
50 ng genomic DNA. The amplification was performed on a
PTC-225 thermal cycler (MJ Research, Waltham, MA),
using a stepdown protocol. The first five cycles were carried
out at 94°C, 65°C, and 72°C, each for 30 s. The next five
cyles were carried out at 94°C, 63°C, and 72°C, each for
30 s. The last 25 cyles were at 94°C, 60°C, and 72°C, each
for 30 s. Following cycling the PCR products were purified
with the Qiagen Qiaquick PCR purification kit (Westburg,
Leusden, the Netherlands). Subsequently, 100 ng of the
purified PCR product was cycle sequenced with a Dyeter-
minator kit (US81090, Amersham Biosciences, Roosendaal,
the Netherlands) in a thermal cycler (MJ Research), using
0.05 mM sequencing primer. For the reverse reaction, the
same primer was used as in the PCR, but for the forward
reaction an internal primer was used (5′-GGTACCAA
CATGGCCCAGAAG). After the cycle reaction the sequenc-
ing products were cleaned on a Sephadex plate (Amersham
Biosciences) by centrifugation for 5 min at 910g. The eluted
sample was vacuum dried for 45 min at 65°C. Finally, 20 μL
of loading solution (Amersham Biosciences) was added to
dissolve the sequencing products. The samples were ana-
lyzed on a MegaBACE 1000 capillary sequencer (Amersham
Biosciences) by injecting the samples for 45 s at 3 kV and
running them for 5 h at 4 kV. The data were processed with
Sequence Analyzer 3.0 (Amersham Biosciences) and
Seqman II (DNASTAR, Madison, WI).
Pharmacokinetic modelling
Pharmacokinetic data were analyzed with the Mw\Pharm
software package (version 3.5; MediWare, Groningen, the
Netherlands) using the KinFit module. For gemcitabine and
its metabolite dFdU, the AUC (using the trapezoid rule),
clearance, distribution volume, and elimination half-lives
were calculated by non-compartmental analysis.
Statistical analysis
Patient data were grouped according to genotype. Differ-
ences in laboratory and demographic data between groups
were tested using the Mann-Whitney test.
CDA genotype-related differences in pharmacokinetic
data were investigated by analyzing the wild type AA
genotype patient group against the combined heterozygote
AC and homozygote CC genotype patient group using the
Mann-Whitney test. We assumed an effect of 30% of the
alternative genotype on the gemcitabine AUC as clinically
relevant. From the literature, the allele frequency of the
wild type genotype was estimated at 0.7, and therefore an
almost equal distribution of patients in AA wild type (49%)
and combined homozygote CC plus heterozygote AC (51%)
patientgroups was expected. We calculated that group sample
sizes of 10 and 10 were needed to achieve 92% power to
detect a difference of 30% between the null hypothesis that
bothgroupmeans are equal andthe alternativehypothesisthat
the mean AUC of the mutant group is 30% larger, with group
standard deviations of 20% and with a significance level of
0.05 using a two-side Mann-Whitney test assuming that the
actual distribution is logistic.
Additionally, differences between uncombined CDA
genotype groups regarding gemcitabine AUC, clearance,
and half-life were also analyzed using the Kruskall-Wallis
test. Statistical analyses were performed using the SPSS
14.0 statistical package (SPSS 2005, Chicago, IL). Power
calculations were performed using NCSS 2004 Statistical &
Power Analysis Software (NCSS, Kaysville, UT).
Results
Patients
A total number of 20 patients were included. Patients were
grouped according to CDA genotype. Patient characteristics
are presented in Table 1.
The groups were comparable with respect to demo-
graphic parameters, renal function, and liver enzymes. All
Eur J Clin Pharmacol (2010) 66:611–617 613patients, except one, had AST levels below the upper limit
of normal. Two patients had a slightly reduced creatinine
clearance (CrCL), between 50 and 60 ml/min. Co-
administration of epirubicin and cisplatin was equally
distributed within and between groups.
Pharmacokinetics
Mean pharmacokinetic curves of gemcitabine and dFdU in
plasma are presented in Fig. 1 according to the different
genotypes. Gemcitabine was rapidly cleared from plasma
and undetectable after 3 h in all patients. The pharmacoki-
netic data are presented in Table 2.
The influence of the presence of epirubine on gemcitabine
pharmacokinetics was checked by grouping the patients
according to treatment schedule (gemcitabine plus cisplatin
orgemcitabine plus epirubicine). No difference in gemcitabine
pharmacokineticswasmeasuredbetweenthetwogroupsusing
the Mann-Whitney U-test.
Pharmacogenetic analysis
The gemcitabine pharmacokinetic data of all 20 patients
were analyzed with respect to the impact of the 79A>C
polymorphism in the CDA gene. The frequencies of the
A/A, A/C, and C/C genotypes were 0.40, 0.40, and 0.20
respectively. The allele frequency of the 79A>C polymor-
phism was 0.40 in our study. Detailed data are presented in
Table 2. The mean pharmacokinetic curves of gemcitabine
and dFdU according to CDA genotype are presented in
Fig. 1. No differences in pharmacokinetic parameters were
observed between the wild type AA genotype group and
the combined heterozygote AC and homozygote CC
genotype group, using the Mann-Whitney test. Additionally,
in the Kruskal-Wallis analysis, we found no significant
differences in gemcitabine AUC, clearance, or serum half-
life among the different CDA genotypes (see Table 2).
Table 1 Patient characteristics
All patients (n=20) Cytidine deaminase genotype subgroups
A/A (n=8) A/C (n=8) C/C (n=4)
Gender (M/F) 17/3 8/0 6/2 3/1
Age (years) 65 (44–73) 67 (55–73) 65 (57–73) 59 (44–73)
Weight (kg) 77 (58–97) 81(60–97) 75 (58–87) 85 (63–88)
Length (cm) 175 (161–192) 177 (168–193) 173 (161–185) 182 (169–192)
BSA (m
2) 1.93 (1.61–2.27) 2.00 (1.69–2.27) 1.90 (1.61–2.03) 2.09 (1.72–2.13)
Creatinine (μmol/l) 78 (49–119) 80 (60–119) 75 (49–99) 81 (66–92)
CrCl (ml/min) (normal: >60) 97 (51–134) 97 (51–130) 88 (64–106) 104 (59–134)
AST (U/l) (normal: <45) 22 (15–35) 22 (12–35) 22 (15–28) 21 (17–27)
ALT (U/l) (normal: <45) 27 (7–47) 23 (7–32) 29 (15–47) 26 (12–36)
Bilirubin (μmol/l) (normal: <20) 10 (6–17) 10 (6–16) 10 (6–17) 10 (9–11)
Co-treatment
Epirubicin 10 5 3 2
Cisplatin 10 3 5 2
Values are medians with the ranges in parentheses
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Fig. 1 Pharmacokinetics of gemcitabine and its metabolite dFdU after
a 30 min infusion of 1,125 mg/m
2 gemcitabine grouped according to
genotype of the cytidine deaminase 79A>C polymorphism
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In this study, we investigated the impact of the common
79A>C nonsynonymous single nucleotide polymorphism
in the cytidine deaminase gene on gemcitabine and dFdU
pharmacokinetics in NSCLC patients. In all patients
gemcitabine was rapidly cleared from plasma, as was
expected from previous reports [13].
The most important factor that determines the clearance rate
of gemcitabine is the activity of CDA. This enzyme rapidly
catabolizes gemcitabine. The totalenzyme capacityofCDA in
all organs and tissues determines the biotransformation rate of
gemcitabine into dFdU and thus the duration of exposure to
gemcitabine. Despite increasing interest in DNA polymor-
phisms related to gemcitabine metabolism, so far only a few
reports have been published on the relation between CDA
polymorphisms and gemcitabine pharmacokinetics.
The 79A>C cSNP is the most common CDA polymor-
phism with previously reported allele frequencies of 0.20 in
Japanese, 0.11 in African Americans, 0.04 in Africans, 0.30
in Caucasian Americans, and 0.36 in European Caucasians
[8, 14–16]. The polymorphism at nucleotide position 79
corresponds to codon27, which is located within an N-
terminal core domain and might be involved in binding
pocket loops that cooperate with zinc ligands [15, 17]. The
A genotype corresponds to the wild type Lys-carrying
enzyme and the C genotype to a Gln-carrying variant
(Gln27 CDA). Kirch et al. found that the deamination rate
of cytarabine by bacterial wild type CDA enzyme was a
1.3–3.3 fold higher than by Gln27 CDA [7]. Gilbert et al.
recently reported in a functional genomics study in
mammalian cells that the activity of human recombinant
Gln27 CDA was about 66% of the wild type CDA activity
for gemcitabine [8]. Thus, assuming highest CDA activity
in A/A, intermediate activity in A/C, and lowest in C/C
diplotypes, we studied the consequences of this polymor-
phism on gemcitabine AUC, clearance, and serum half-life.
All patients in our study were Caucasian Europeans, and in
this group we found an allele frequency of 0.40, which is in
line with the allele frequencies of 0.30 and 0.36 earlier
reportedforCaucasians[8, 16]. We did, however, not observe
an impact of the CDA 79A>C genotype on gemcitabine
pharmacokinetics. Obviously, our study was powered to
detect differences of at least 30% in population means and
smaller differences in pharmacokinetic parameters may have
gone unnoticed. In the post-hoc statistical analysis, we found
a much larger variation in gemcitabine AUC values, ranging
from 30–50%, than the initially expected 20%. As a result
we achieved only 25% power to detect a difference. We
reasoned however that, due to the fact that the data in both
groups largely overlap, it seems very unlikely that dose
adjustment according to CDA genotype will become
clinically feasible, if a difference might exist.
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Eur J Clin Pharmacol (2010) 66:611–617 615Interestingly, this matter has recently been elucidated, as,
in parallel with our study, Sugiyama et al. investigated the
79A>C polymorphism in a population of 251 Japanese
patients. In line with our data, they could not detect any
effect of the 79A>C polymorphism on the gemcitabine
pharmacokinetics after a 30 min 800–1,000 mg/m
2 infusion
[14]. It is important to realize that the two studies differ
with respect to administered gemcitabine dose and patient
ethnicity. The mean dose in our study was 38% higher as a
result of both a higher standard dose (1,125 mg/m
2) and
generally higher body surface area (BSA) values in
Caucasians. Obviously, these factors do not change or
modulate the observed lack of impact on pharmacokinetic
outcomes of the 79A>C polymorphism.
One explanation for our findings may be a far more
complex regulation of CDA gene transcription, leading to
substantial interindividual differences in quantities of CDA
enzyme, unrelated to the 79A>C polymorphism. Although
Kirch et al. [8] and Gilbert et al. [9] demonstrated reduced
enzyme activity with the 79A>C polymorphism using in
vitro deamination of ara-C and dFdC, respectively, it is
possible that additional polymorphisms within CDA also
influence enzyme activity or that variants in other enzymes
in gemcitabine metabolism play a greater than expected
role. Other studies have shown that the CDA ‘5 flanking
region contains numerous potential transcription factor
binding sites that can cause variations in transcription
[18]. Unfortunately, we did not perform direct measurement
of CDA activity in our patients and thus could not check
the genotype-phenotype relation at the enzyme level.
Moreover, we hypothesized that possibly the total
capacity of CDA in the body may far exceed the amount
needed to cope with plasma levels resulting from 800–
1,125 mg/m
2 gemcitabine doses. In that case, differences in
pharmacokinetics may only become manifest at much
higher plasma concentrations when Michaelis-Menten
enzyme saturation is becoming relevant.
Finally, the pharmacokinetic results might have been
dispersed as a result of co-administration of other chemother-
apeutic agents. Indeed, all patients in our study received
combined chemotherapy, but cisplatin was administered on
day 2 and therefore did not interact with our results. We
analyzedthatco-administrationofepirubicindidnotinfluence
the pharmacokinetics of gemcitabine, which is in line with
previously reported findings regarding the pharmacokinetics
of both drugs when combined intreatment schedules [19–21].
Although we could not demonstrate an effect of the
CDA 79A>C polymorphism on gemcitabine pharmacoki-
netics, the polymorphism still may be relevant at the
cellular level. Bathla et al. recently demonstrated that the
post-induction treatment-related mortality in children trea-
ted for acute myeloid leukemia with high dose cytarabine
was significantly higher in children bearing the CC
compared to the AC or AA genotype [22]. Cytarabine and
gemcitabine share a common metabolic pathway. Further-
more, Tibaldi et al. showed that the wild type CDA
Lys27Lys (AA) genotype was associated with better clinical
outcome, longer time to progression, and overall survival
[23]. Interestingly, they also found an increased CDA
enzymatic activity in red blood cells associated with the
CDA Gln/Gln (CC) genotype. Although these findings
contradict previous results from in-vitro functional
genomics experiments by Kirch et al. and Gilbert et al.,
this clinical study illustrates that the association between
genotype and treatment efficacy may be quite complex.
Recently two new polymorphisms in the CDA gene were
reported. These concern the 208G>A and 435T>C polymor-
phism with allele frequencies of 0.04 and 0.30 in Japanese
patients, respectively [15]. The 208G>A polymorphism
produces an alanine-to-threonine substitution (Ala70Thr)
within the conserved catalytic domain. Introduction of this
gene in yeast null mutants resulted in a 20% reduction of the
50% inhibitory concentration value for cytarabine [15].
Sugiyama et al. also studied both variants and found a
decreased gemcitabine clearance in patients with the 208G>A
polymorphism [14]. However, the 208G>A polymorphism
has not been detected so far in Caucasians and was therefore
not included in our study. The 435T>C polymorphism
(Thr145Thr) does not encode for an amino acid change.
Since an impact of this silent 425T>C polymorphism on
CDA enzyme activity was expected to be less probable, we
did not include this polymorphism in our investigations.
Conclusions
We conclude that the common 79A>C CDA polymorphism
does not have a major consistent, significant effect on
gemcitabine plasma clearance. The full pharmacogenetic
picture of CDA in relation to gemcitabine clearance and
gemcitabine pharmacodynamics may nevertheless be quite
complex and can only be elucidated in large clinical trials.
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